Legend Biotech Corporation (LEGN)
Develops CAR-T cell therapies that reprogram immune cells to fight cancer.
$18.77-0.03%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-51.6%
The outlook
Legend Biotech trades at $18.77, sitting well below its 50- and 200-day moving averages and near the lower end of its 52-week range. Analyst consensus is bullish with a Buy rating, and the average price target sits about 189% above current levels. The overall score reflects mixed signals between strong analyst sentiment and weak recent price momentum.
What’s behind the score
Analyst consensusBuy — 1.9 avg of 15 analysts
Price trendBelow its 50- & 200-day averages
52-week range10% of the way from its 52-week low to high
Price targetAvg target +189% vs current price
Analyst price target
~12-month · 15 analysts$54.23average target+189.0% vs now
Now $18.77
Low $27.00High $86.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$3.63B
52-wk high
$42.26
52-wk low
$16.24
50-day avg
$28.64
200-day avg
$24.81
Trailing P/E
—